Pfizer (PFE) Competitors $24.72 -0.07 (-0.26%) Closing price 10/13/2025 03:59 PM EasternExtended Trading$24.59 -0.13 (-0.52%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PFE vs. AMGN, GILD, MRNA, NVAX, VTRS, ABBV, BMY, JNJ, LLY, and MRKShould you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), Viatris (VTRS), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Merck & Co., Inc. (MRK). These companies are all part of the "medical" sector. Pfizer vs. Its Competitors Amgen Gilead Sciences Moderna Novavax Viatris AbbVie Bristol Myers Squibb Johnson & Johnson Eli Lilly and Company Merck & Co., Inc. Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings. Which has stronger valuation and earnings, AMGN or PFE? Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.71$4.09B$12.2323.91Pfizer$63.63B2.21$8.03B$1.8813.15 Do analysts prefer AMGN or PFE? Amgen presently has a consensus price target of $309.42, indicating a potential upside of 5.82%. Pfizer has a consensus price target of $28.35, indicating a potential upside of 14.72%. Given Pfizer's stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35Pfizer 1 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.37 Is AMGN or PFE a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.0%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the media refer more to AMGN or PFE? In the previous week, Pfizer had 24 more articles in the media than Amgen. MarketBeat recorded 84 mentions for Pfizer and 60 mentions for Amgen. Pfizer's average media sentiment score of 1.11 beat Amgen's score of 1.09 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 44 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 57 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, AMGN or PFE? Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Is AMGN or PFE more profitable? Amgen has a net margin of 18.96% compared to Pfizer's net margin of 16.84%. Amgen's return on equity of 174.71% beat Pfizer's return on equity.Company Net Margins Return on Equity Return on Assets Amgen18.96% 174.71% 13.12% Pfizer 16.84%21.42%9.12% Do insiders & institutionals have more ownership in AMGN or PFE? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.7% of Amgen shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAmgen and Pfizer tied by winning 10 of the 20 factors compared between the two stocks. Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFE vs. The Competition Export to ExcelMetricPfizerLarge Cap Pharma IndustryMedical SectorNYSE ExchangeMarket Cap$140.89B$271.03B$6.05B$21.48BDividend Yield6.94%2.60%5.73%3.67%P/E Ratio13.1531.1085.1429.66Price / Sales2.215.20607.1786.18Price / Cash5.6814.5525.7717.79Price / Book1.5819.7912.644.63Net Income$8.03B$8.49B$3.32B$1.01B7 Day Performance-5.92%-1.73%-0.07%-0.80%1 Month Performance3.37%3.13%8.70%0.55%1 Year Performance-15.01%-4.77%78.24%13.03% Pfizer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFEPfizer4.9651 of 5 stars$24.72-0.3%$28.35+14.7%-15.2%$140.89B$63.63B13.1581,000Trending NewsDividend AnnouncementAnalyst RevisionAMGNAmgen4.5467 of 5 stars$295.65-1.0%$309.70+4.8%-10.9%$159.37B$33.42B24.2128,000Positive NewsAnalyst DowngradeAnalyst RevisionGILDGilead Sciences4.877 of 5 stars$109.48-1.5%$117.17+7.0%+39.2%$136.11B$28.75B21.8517,600Positive NewsMRNAModerna4.2441 of 5 stars$28.11+1.8%$41.81+48.8%-54.1%$10.92B$3.24B-3.735,800NVAXNovavax4.2364 of 5 stars$9.45-0.5%$14.29+51.1%-31.2%$1.54B$682.16M4.151,990VTRSViatris1.7263 of 5 stars$10.090.0%$10.40+3.1%-13.4%$11.78B$14.74B-3.4832,000ABBVAbbVie4.6088 of 5 stars$236.29-3.3%$223.52-5.4%+18.6%$418.78B$56.33B112.8955,000Trending NewsAnalyst DowngradeAnalyst RevisionBMYBristol Myers Squibb4.9854 of 5 stars$45.80-3.4%$56.38+23.1%-16.6%$93.42B$48.30B18.5134,100Trending NewsAnalyst ForecastAnalyst RevisionJNJJohnson & Johnson4.6668 of 5 stars$185.68-0.2%$181.40-2.3%+18.2%$447.52B$88.82B19.87138,100Trending NewsLLYEli Lilly and Company4.9964 of 5 stars$820.01-0.7%$939.61+14.6%-12.2%$776.30B$45.04B53.6147,000Trending NewsAnalyst RevisionMRKMerck & Co., Inc.4.9971 of 5 stars$89.18-1.1%$106.41+19.3%-22.0%$222.94B$64.17B13.7575,000Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Moderna Alternatives Novavax Alternatives Viatris Alternatives AbbVie Alternatives Bristol Myers Squibb Alternatives Johnson & Johnson Alternatives Eli Lilly and Company Alternatives Merck & Co., Inc. Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PFE) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
